Innealta Capital LLC Purchases New Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Innealta Capital LLC bought a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,731 shares of the company’s stock, valued at approximately $119,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. F M Investments LLC purchased a new position in Prestige Consumer Healthcare in the second quarter valued at about $11,162,000. Miller Howard Investments Inc. NY grew its stake in Prestige Consumer Healthcare by 2.2% in the second quarter. Miller Howard Investments Inc. NY now owns 7,762 shares of the company’s stock valued at $534,000 after purchasing an additional 165 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in Prestige Consumer Healthcare by 26.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,320,125 shares of the company’s stock valued at $90,891,000 after purchasing an additional 272,773 shares in the last quarter. Bailard Inc. purchased a new position in Prestige Consumer Healthcare in the second quarter valued at about $213,000. Finally, Louisiana State Employees Retirement System grew its stake in Prestige Consumer Healthcare by 2.0% in the second quarter. Louisiana State Employees Retirement System now owns 25,100 shares of the company’s stock valued at $1,728,000 after purchasing an additional 500 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on PBH shares. DA Davidson boosted their target price on Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday. Canaccord Genuity Group reiterated a “buy” rating and set a $80.00 price target on shares of Prestige Consumer Healthcare in a research note on Tuesday, May 21st. Finally, StockNews.com downgraded Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 21st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $98.75.

Prestige Consumer Healthcare Stock Up 0.9 %

Shares of PBH traded up $0.64 during trading hours on Friday, hitting $74.64. 232,419 shares of the company were exchanged, compared to its average volume of 248,855. The company has a market cap of $3.71 billion, a PE ratio of 17.87, a PEG ratio of 1.94 and a beta of 0.49. The firm’s 50 day moving average is $69.60 and its 200-day moving average is $69.18. Prestige Consumer Healthcare Inc. has a 52 week low of $56.34 and a 52 week high of $75.31. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.90 and a current ratio of 3.23.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.86 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.55% and a net margin of 18.43%. The firm had revenue of $267.10 million during the quarter, compared to the consensus estimate of $260.54 million. During the same quarter in the prior year, the company earned $1.06 EPS. The firm’s revenue for the quarter was down 4.4% compared to the same quarter last year. On average, equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.42 EPS for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.